Novo Nordisk has reported another significant criticality: the presence of unauthorized versions of its drugs on the US ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...

Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Trump sent the request to 17 companies, including Sanofi, AstraZeneca, GSK, Merck KGaA and Novo Nordisk from the European ...

AI and semiconductor stocks are overvalued and shifting to healthcare stocks like Eli Lilly and Company could be wise. Click ...

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The Trump administration is evaluating a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, ...